NEW YORK (GenomeWeb) – AstraZeneca will use Bina Technologies' genome analysis software as an enterprise platform to support its development work across three therapeutic areas, the companies said today.

Under the collaboration agreement, the pharma company will adopt the Bina Genomic Management Solution (GMS) globally to support genomic data analysis and management as part of its development of drugs in oncology, cardiovascular and metabolic disease, respiratory disease, inflammation, and autoimmunity. AstraZeneca will also become the first member of the Bina Alliance Program.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.